Macular degeneration trials in China

In China 37 Also abroad 218

37 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Where
Shanghai
Age
50 years and over
People
272 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07441642 · EU 2025-523704-77-00
Phase 1Taking people
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
Where
Chengdu
Age
50 years and over
People
18
Run by
InnoVec Biotherapeutics Inc.
See details and how to joinNCT06737354
Phase 2/3Taking people
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Where
Beijing, Chengdu, Shanghai
Age
60 years and over
People
274 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00
Phase 1/2Taking people
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Where
Beijing
Age
50 years to 85 years
People
198
Run by
Fujian Haixi Pharmaceuticals Co., Ltd.
See details and how to joinNCT07185841
Phase 1/2Taking people
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Where
Nanjing
Age
50 years to 85 years
People
12
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07418177
Phase 1Not yet taking people in China
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
Where
Shanghai
Age
18 years to 85 years
People
60
Run by
Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT07817615
No phaseTaking people
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Where
Beijing, Hangzhou, Hefei, Shanghai, Wenzhou
Age
50 years and over
People
83 worldwide
Run by
Skyline Therapeutics
See details and how to joinNCT06346600
Phase 1/2Taking people
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Where
Beijing, Hangzhou, Hefei, Wenzhou
Age
50 years and over
People
68 worldwide
Run by
Skyline Therapeutics (US) Inc.
See details and how to joinNCT05986864
Phase 2Taking people
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
Where
Beijing, Chengdu, Chongqing, Harbin, Jilin City, Kunming, Nanjing, Shanghai, Shantou, Taiyuan, Tianjin, Wuhan, Zhejiang, Zhengzhou
Age
50 years to 85 years
People
50
Run by
West China Hospital
See details and how to joinNCT07776522
Phase 3Taking people
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi’an, Xingtai, Xuzhou, Zhongshan
Age
50 years to 80 years
People
388
Run by
Innostellar Biotherapeutics Co.,Ltd
See details and how to joinNCT07317934
No phaseTaking people
Real-world Study of Aflibercept 8 mg in nAMD
Where
Beijing, Chengdu, Dalian, Fuzhou, Harbin, Hohhot, Jinan, Nanyang, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi’an, Zunyi
Age
50 years and over
People
300
Run by
Peking University People's Hospital
See details and how to joinNCT07640997
No phaseNot yet taking people in China
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
Where
Shanghai
Age
50 years to 85 years
People
200
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07328776
No phaseNot yet taking people in China
Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
Where
Guangzhou
Age
50 years and over
People
50
Run by
Sun Yat-sen University
See details and how to joinNCT07581782
No phaseNot yet taking people in China
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy
Where
Shanghai
Age
50 years to 80 years
People
62
Run by
Shanghai Institute of Acupuncture, Moxibustion and Meridian
See details and how to joinNCT07570355
Early phase 1Taking people
Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
Where
Shanghai
Age
50 years and over
People
10
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07053358
No phaseNot yet taking people in China
Repeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration
Where
Hong Kong
Age
50 years and over
People
94
Run by
The Hong Kong Polytechnic University
See details and how to joinNCT07409389
Phase 1Not yet taking people in China
To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Where
Beijing, Guiyang, Hangzhou, Nanchang, Zhengzhou
Age
50 years to 80 years
People
48
Run by
Shenzhen Kexing Pharmaceutical Co., Ltd.
See details and how to joinNCT07406438
Phase 4Not yet taking people in China
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
Where
Beijing, Foshan, Hangzhou, Harbin, Jiaxing, Jilin City, Jinan, Kunming, Nanchang, Nanjing, Shanghai, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xianyang, Zhengzhou
Age
50 years and over
People
174
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07365371
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Where
Shanghai
Age
50 years and over
People
800
Run by
Innovent Biologics Technology Limited (Shanghai R&D Center)
See details and how to joinNCT07275840
No phaseTaking people
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
Where
Shanghai
Age
50 years to 85 years
People
24
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT05465252
No phaseTaking people
Natural History Study of Inherited Retinal Diseases
Where
Wuhan
People
200
Run by
Augelux Therapeutics
See details and how to joinNCT07085533
Phase 3Taking people
QA108 Phase III Study in Subjects With Intermediate AMD
Where
Beijing
Age
45 years to 85 years
People
400
Run by
Smilebiotek Zhuhai Limited
See details and how to joinNCT07189169
Phase 1/2Taking people
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Where
Tianjing
Age
45 years to 80 years
People
82
Run by
Sinocelltech Ltd.
See details and how to joinNCT06672536
Early phase 1Taking people
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
Where
Shanghai
Age
6 years to 17 years
People
6
Run by
HuidaGene Therapeutics Co., Ltd.
See details and how to joinNCT07063251
No phaseTaking people
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Where
Beijing
Age
50 years and over
People
42
Run by
Guangzhou Jiayin Biotech Ltd
See details and how to joinNCT06859515